SCA
CTMX icon

Secor Capital Advisors’s CytomX Therapeutics CTMX Stock Holding History

Secor Capital Advisors’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-18,839
Closed -$203K – 81
2019
Q1 		$203K Buy
18,839
+1,822
+11% +$26.9K 0.04% 364
2018
Q4 		$257K Buy
+17,017
New +$252K 0.03% 390
2018
Q2 		– Sell
-43,228
Closed -$1.23M – 524
2018
Q1 		$1.23M Buy
+43,228
New +$1.23M 0.1% 265

Other funds holding CTMX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Secor Capital Advisors's CTMX Position: Q2 2019 in Review

Secor Capital Advisors sold out of CytomX Therapeutics (CTMX) in Q2 2019, closing a stake of 18,839 shares — an estimated $203K sold.

Secor Capital Advisors first reported a position in CTMX in Q1 2018 and held it in 3 quarters. The position peaked at $1.23M in Q1 2018. 109 funds tracked by Wall St. Rank hold CTMX as of Q2 2019.

  • Secor Capital Advisors reported no remaining CytomX Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Secor Capital Advisors sold 18,839 CytomX Therapeutics shares in Q2 2019, an estimated $203K.
  • Secor Capital Advisors first reported a position in CytomX Therapeutics in Q1 2018 and held it in 3 quarters.
  • Secor Capital Advisors's CytomX Therapeutics position peaked at $1.23M in Q1 2018.
  • 109 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2019.

Based on Secor Capital Advisors's 13F filing for Q2 2019.